<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03921099</url>
  </required_header>
  <id_info>
    <org_study_id>208</org_study_id>
    <nct_id>NCT03921099</nct_id>
  </id_info>
  <brief_title>Impact of Ascorbic Acid in the Prevention of Vancomycin Induced Nephrotoxicty</brief_title>
  <official_title>Evaluation of the Impact of Ascorbic Acid in the Prevention of Vancomycin Induced Nephrotoxicity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized controlled trial aiming to investigate whether ascorbic acid has a role in
      preventing vancomycin induced nephrotoxicity or not in critically ill patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Critically ill patients who have gram positive infection (MRSA) and need vancomycin will be
      assigned randomly into two groups. The first group will be given vancomycin intravenous only
      (15-20 mg/kg) every 8-12 hours , while the second group will take vancomycin intravenous
      (15-20 mg/kg) every 8-12 hours plus ascorbic acid 1 gram twice daily orally just before the
      vancomycin administration by half an hour. Patients will be monitored for one week where
      serum creatinine, BUN, urine output, trough level will be measured. Acute kidney injury will
      be determined according to RIFLE criteria.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 17, 2019</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of nephrotoxicty</measure>
    <time_frame>one week</time_frame>
    <description>Incidence of nephrotoxicty will be described according to RIFLE criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>28 days Mortality</measure>
    <time_frame>one month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>Vancomycin only</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Vancomycin 15-20mg/kg intravenous every 8-12 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vancomycin +Ascorbic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vancomycin 15-20mg/kg intravenous every 8-12 hours. Ascorbic acid 1gm every 12 hours orally just before vancomycin by half an hour for seven days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ascorbic Acid</intervention_name>
    <description>ascorbic acid is an antioxidant that is expected to prevent nephrotoxicty induced by Vancomycin.</description>
    <arm_group_label>Vancomycin +Ascorbic acid</arm_group_label>
    <other_name>Vitamin C</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults who are critically ill and with MRSA infection suspection.

        Exclusion Criteria:

          1. Pregnancy or breast feeding.

          2. Known allergy to either vancomycin or ascorbic acid.

          3. Base line serum creatinine â‰¥2mg/dl.

          4. Patients receiving other nephrotoxic drug (e.g., aminoglycosides, amphotericin B,
             cisplatin or calcinurine inhibitors).

          5. Anticepated administration of contrast medium within 7 days.

          6. Patients suffering from some underlying diseases (e.g., cancer, HIV infection,
             systemic lupus erythematoses,or urinary tract stones).

          7. Unlikelyhood of receiving the study medications for at least 72 hours
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nagwa A Sabry, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Ain Shams University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sara M Shaheen, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Ain Shams University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nouran H Elsherazy, Bachelor</last_name>
    <phone>+201224959630</phone>
    <email>Nouran_elsherazy@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Naglaa S Bazan, PhD</last_name>
    <email>NaglaaBazan@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cairo university hospitals</name>
      <address>
        <city>Cairo</city>
        <zip>11562</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Critical care department Cairo university Hopsitals</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>April 16, 2019</study_first_submitted>
  <study_first_submitted_qc>April 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2019</study_first_posted>
  <last_update_submitted>January 8, 2020</last_update_submitted>
  <last_update_submitted_qc>January 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Nouran Hesham Ali</investigator_full_name>
    <investigator_title>clinical pharmacist at the critical care medicine unit- Cairo university hospitals</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

